Precision BioSciences Inc (DTIL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $288.76M
Last updated: Nov 17, 2026 at 11:04 AM ET
Precision BioSciences Inc (DTIL) Stock Forecast
Analysts expect Precision BioSciences (DTIL) to earn -$2.85 per share in the fiscal year ending Dec 31, 2026, on revenue of $11.35M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 23.0%.
- Fiscal year ending Dec 31, 2026
- -$2.85
- EPS consensus, revenue $11.35M
- Fiscal year ending Dec 31, 2027
- -$2.19
- EPS consensus, revenue $8.74M
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.85 | -$3.11 to -$2.58 | 4 | $11.35M | $10.80M to $13.30M | 5 |
| Dec 31, 2027 | -$2.19 | -$3.38 to -$1.59 | 4 | $8.74M | N/A | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.83 for the quarter ending Dec 31, 2026 to -$0.42 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.83 | -$1.18 to -$0.58 | 7 | $1.02M | N/A | 7 |
| Mar 31, 2027 | -$0.42 | -$0.42 to -$0.42 | 1 | N/A | N/A | 1 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.38.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.85 | -$3.87 | -$3.87 | -$3.87 | -$3.38 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.19 | -$1.86 | -$1.86 | -$1.86 | -$2.14 | N/A |
| Quarter ending Mar 31, 2027 | -$0.42 | -$0.39 | -$0.39 | -$0.39 | -$0.57 | N/A |
Frequently Asked Questions About DTIL
What is the DTIL stock forecast?
Consensus analyst estimates put Precision BioSciences's EPS at -$2.85 for the fiscal year ending Dec 31, 2026, on revenue of $11.35M. The consensus rating from 5 analysts is Buy.
How do analysts rate DTIL stock?
Of 5 analysts covering Precision BioSciences, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DTIL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.85, with estimates from -$3.11 to -$2.58 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.19, with estimates from -$3.38 to -$1.59 from 4 analysts.
What revenue do analysts expect from Precision BioSciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $11.35M, with estimates from $10.80M to $13.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $8.74M.
How many analysts cover DTIL?
5 analysts rate Precision BioSciences stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DTIL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors